

U.S. Oncologists See Promise in Cell and Gene Therapy, but Barriers Loom

Results of 2024 Survey

99%



of oncologists agree that CGTs are among the **most important medical innovations of our time.**

94%



agree that CGTs have the potential to **dramatically improve patients' quality of life.**

3 out of 5



physicians say patients they refer for CGTs **often receive other treatments instead.** When asked why, they cite insurance coverage and out-of-pocket costs as the most common reasons.

47%



of oncologists say that patients are **“rarely” or “never” aware that CGTs are available for their condition.**

64%



agree that **CGTs are not easily accessible for patients** who meet the labeled indications.

Top reasons oncologists choose not to prescribe:



54% have concerns about the **safety profile**

53% have concerns about the **side effect profile**



Scan to download the 2024
Cell and Gene Therapy Report

McKesson conducted an online survey of 124 U.S. oncologists in June and July 2024. Participants represented a range of geographies, years in practice and practice sizes.

© 2024 McKesson Corporation. All rights reserved.

InspiroGene™

By McKesson